Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Pushed back the final finish date by about 24 months: Dec 2026 → Dec 2028.

The company moved the expected finish date for its study of R289 in people with lower-risk myelodysplastic syndromes (a group of blood disorders) from December 2026 to December 2028, a delay of about 24 months. Investors watch changes like this because a longer timeline can hint that patients are joining more slowly than planned or that the study design is being reworked, which could mean results come later and cost more. A date moving can also have ordinary causes, such as scheduling adjustments or paperwork, and the company hasn't said why it changed, so this alone doesn't show whether the study is in trouble.

AI-written from the facts above

Spotted on Nov 6, 2026

Pushed back the main results date by about 16 months: Aug 2026 → Dec 2027.

A drug study from Rigel Pharmaceuticals has pushed back the date when its main results are expected, from August 2026 to December 2027, a delay of about 16 months. Investors often watch changes like this because a delay can sometimes mean the study is taking longer than planned, perhaps due to trouble finding or keeping patients, or because the company is adjusting how it will judge the drug, and either could point to a weaker outlook than expected. But schedules shift for many ordinary reasons, such as slower patient sign-ups or simple planning updates, and the company hasn't said why this one moved, so a later date on its own doesn't prove anything about the drug or the company.

AI-written from the facts above

Spotted on Nov 6, 2026